Key Market Indicator:
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Wed, 13.07.2022
Deutsche Rohstoff AG
First Berlin Equity Research hat ein Research Update zu Deutsche Rohstoff
AG (ISIN: DE000A0XYG76) veröffentlicht. Analyst Simon Scholes bestätigt
seine BUY-Empfehlung und senkt das Kursziel von EUR 43,00 auf EUR 36,00.
Zusammenfassung:
Die vorläufigen Ergebnisse für Q2/22 zeigen einen Anstieg des EBITDAs um
83,4 % auf €3 [ … ]
Wed, 13.07.2022
Advanced Blockchain AG
The Gateway to DeFi, Crypto & Web 3.0. Significant upside potential due to
the well diversified portfolio. Successful partial divestments and
financing rounds confirm the Group's investment approach.
Advanced blockchain AG is a blockchain venture builder focused on
investing, developing, and scaling in disruptive technologies including
token [ … ]
Wed, 13.07.2022
Advanced Blockchain AG
The Gateway to DeFi, Crypto & Web 3.0. Significant upside potential due to
the well diversified portfolio. Successful partial divestments and
financing rounds confirm the Group's investment approach.
Advanced blockchain AG is a blockchain venture builder focused on
investing, developing, and scaling in disruptive technologies including
token [ … ]
Wed, 13.07.2022
MagForce AG
- Stage 2b of the trial for approval in the USA is currently ongoing
- Billing code by the American Medical Association is available
- Break-even expected from 2024
In the past financial year 2021, MagForce AG continued or resumed the
planned European roll-out for the treatment of malignant brain tumours
(glioblastoma). The four NanoActivator de [ … ]
Wed, 13.07.2022
MagForce AG
- Stage 2b of the trial for approval in the USA is currently ongoing
- Billing code by the American Medical Association is available
- Break-even expected from 2024
In the past financial year 2021, MagForce AG continued or resumed the
planned European roll-out for the treatment of malignant brain tumours
(glioblastoma). The four NanoActivator de [ … ]
Wed, 13.07.2022
wallstreet:online AG
13/07/2022 - Management interview with wallstreet:online AG
'We see ourselves as a next generation broker and disruptor of the classic
broker market in Germany. The transaction business will account for the
largest share of our revenues in a few years. '
wallstreet:online AG (wallstreet:online) operates Smartbroker - a multiaward
-winning onli [ … ]
Wed, 13.07.2022
wallstreet:online AG
13/07/2022 - Management interview with wallstreet:online AG
'We see ourselves as a next generation broker and disruptor of the classic
broker market in Germany. The transaction business will account for the
largest share of our revenues in a few years. '
wallstreet:online AG (wallstreet:online) operates Smartbroker - a multiaward
-winning onli [ … ]
Tue, 12.07.2022
Advanced Blockchain AG
Advanced Blockchain AG, is an agile venture builder and investor in the
blockchain ecosystem. The company is equipped with a comprehensive team of
developers, researchers, auditors, economists, and mathematicians that are
dedicated to engineering the future of our internet - termed 'Web3'.
The company announced important strategic adjustments to [ … ]
Tue, 12.07.2022
Advanced Blockchain AG
Advanced Blockchain AG, is an agile venture builder and investor in the
blockchain ecosystem. The company is equipped with a comprehensive team of
developers, researchers, auditors, economists, and mathematicians that are
dedicated to engineering the future of our internet - termed 'Web3'.
The company announced important strategic adjustments to [ … ]
Mon, 11.07.2022
Formycon AG
First Berlin Equity Research hat ein Research Update zu Formycon AG (ISIN:
DE000A1EWVY8) veröffentlicht. Analyst Simon Scholes bestätigt seine
BUY-Empfehlung und erhöht das Kursziel von EUR 89,00 auf EUR 97,00.
Zusammenfassung:
Die britische Aufsichtsbehörde genehmigte das Lucentis-Biosimilar FYB201
von Formycon im Mai, und d [ … ]